Patients with Multiple Myeloma and Prior COVID-19 Have Superior Antibody Responses Against Sars-Cov-2 Compared with Fully Vaccinated Myeloma Patients with the BNT162b2 Vaccine

Introduction: Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with multiple myeloma (MM), especially under treatment. Herein, we evaluated the development of neutralizing antibodies (NAbs) against SARS-CoV-2 in non-vaccinated MM patients who were diagnosed with...

Descripción completa

Detalles Bibliográficos
Autores principales: Gavriatopoulou, Maria, Terpos, Evangelos, Malandrakis, Panagiotis, Ntanasis-Stathopoulos, Ioannis, Briasoulis, Alexandros, Gumeni, Sentiljana, Fotiou, Despina, Papanagnou, Eleni-Dimitra, Migkou, Magdalini, Theodorakakou, Foteini, Eleutherakis-Papaiakovou, Evangelos, Kanellias, Nikolaos, Trougakos, Ioannis P., Kastritis, Efstathios, Dimopoulos, Meletios-Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
652.Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701578/
http://dx.doi.org/10.1182/blood-2021-145487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701578/
http://dx.doi.org/10.1182/blood-2021-145487

Ejemplares similares